← All trials
NCT05944562
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 31, 2023
- Primary completion
- Jan 31, 2028
- Completion date
- Dec 31, 2029
- First posted
- Jul 13, 2023
- Last posted
- Nov 27, 2023
- Enrollment
- 30
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Washington University in St. LouisLead sponsor
- MorphoSysCollaborator
- Washington University in St. LouisCollaborator
- Washington University in St. LouisOverall official - principal investigator
- Washington University in St. LouisOfficial
- Swim Across AmericaCollaborator
- NovartisCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.